In-silico study of approved drugs as potential inhibitors against 3CLpro and other viral proteins of CoVID-19.
The global pandemic, due to the emergence of COVID-19, has created a public health crisis. It has a huge morbidity rate that was never comprehended in the recent decades. Despite numerous efforts, potent antiviral drugs are lacking. Repurposing of drugs presents a low-cost and rapid solution for fin...
Saved in:
| Main Authors: | Imra Aqeel, Abdul Majid, Tahani Jaser Alahmadi, Areej Althubaity |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0325707 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
α-Heteroarylthiomethyl ketones: Small molecule inhibitors of 3CLpro
by: Knez Damijan, et al.
Published: (2025-06-01) -
Discovery of 3CLpro inhibitor of SARS-CoV-2 main protease
by: Yi Kuang, et al.
Published: (2023-04-01) -
Accessible interactive learning of mathematical expressions for school students with visual disabilities
by: Amjad Ali, et al.
Published: (2024-12-01) -
Drug repurposing targeting COVID-19 3CL protease using molecular docking and machine learning regression approaches
by: Imra Aqeel, et al.
Published: (2025-05-01) -
In silico repurposing of FDA-approved drugs as multi-target inhibitors of glioblastoma
by: Ridwan Abiodun Salaam, et al.
Published: (2025-03-01)